AGS Tx

AGS Therapeutics develops innovative human therapeutics, vaccines and gene therapies based on the outstanding features of the MEVs (microalgae extracellular vesicles).

MEVs are a safe, targeted and highly versatile delivery system for innovative biologics, such as mRNA, siRNA, DNA, peptides, and proteins for a broad range of human diseases.
Some relevant features of MEVs, such as their oral availability, their fine-tune access to the spleen, or their capacity to easily target selected regions of the brain, open new unexpected avenues for the treatment and prevention of severe human conditions.

AGS’ MEVs are easy to manufacture in large quantities with production techniques that are easily scalable and industrializable.
AGS’ MEVs are derived from Chlorella, a two-billion-year-old single-cell algae used for decades as a food supplement. Production of AGS’ MEVs is a simple, green, eco-friendly activity that requires water, minerals, and light, only.

AGS-M is a subsidiary company of AGS Therapeutics, fully dedicated to the development of suitable processes for the bioproduction - purification of MEVs, and to the manufacturing of MEV batches aimed at supporting the preclinical and clinical development of MEV-based products from AGS Therapeutics and its pharma partners.